Monoclonal Anti-KLK2 Antibody, Rabbit (M1D12)

Ce produit est en cours de développement. Si vous êtes intéressé par ce produit, veuillez nous contacter directement. Nous accélérerons le processus R&D selon vos besoins et réserverons le produit pour vous.
Numéro de produit/spécification
Prix
Availability
Qté
HGS-M2817-20ul
$185.00
HGS-M2817-100ul
$485.00
Montant du produit:
$ 0
Précommande
  • Détails du produit
  • Affichage des données
  • Reviews & Citations
  • Important Statement
  • Resources
Source

Monoclonal Anti-KLK2 Antibody, Rabbit (M1D12) is a recombinant KLK2 primary antibody for IHC application.

Antibody Type

Recombinant Monoclonal

Clone

M1D12

Isotype

Rabbit IgG, Kappa

Host Species

Rabbit

Reactivity

Human

Specificity

React with KLK2 protein on the membrane and intracellular area of target cell/tissue.

Purification

Protein A purified.

Concentration

0.9~1.1 mg/ml

Form

Liquid

Formulation

Please contact us for detailed information.

Contact us for customized product form or formulation.

Shipping

Liquid product is shipped at blue ice.

Storage

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • 2°C to 8°C for 14 days;
  • -20°C to -70°C for 12 months.
Notices

Product Specific Notices: For research use only.

Introduction de fond

KLK2 encodes kallikrein-related peptidase 2, a highly active trypsin-like serine protease that selectively cleaves at arginine residues. It belongs to the kallikrein family and is primarily expressed in prostatic tissue, where it participates in proteolytic processing. KLK2 protein is found in the extracellular region, extracellular exosomes, and secretory granules. A central function of KLK2 is cleavage of pro-prostate-specific antigen into its enzymatically active form, placing it in zymogen activation and proteolysis. Its selective expression in the male reproductive system supports its role in reproductive tissue biology. Pathogenic relevance for KLK2 is reported in soft tissue sarcoma, and the gene is highly expressed in prostate tumor cells, where it has been described as a prognostic marker for prostate cancer risk.

ACRO Scientific Leadership Award

Supporting the scientists driving cell & gene therapy forward

Apply Now